An independent reference for the GLP‑1 decision

We rate online GLP-1 programs on one published rubric and put them in one order. Each review states the standing monthly price, the medications dispensed, the pharmacy that fills them, the states served and the FDA record, with the date every figure was read. The result is a ranking a reader can reproduce from the table beneath it.

Every price is read from the program’s own pricing page and stored with the date and the URL it was read from. The weekly Check re-reads every program and sends any change to a person before a published figure moves. A price here can be a few days behind the program’s own site. It is never a number nobody checked.

We convert the CMS National Average Drug Acquisition Cost from a rate per milliliter to a cost per pen and per package, using the pack sizes in the FDA National Drug Code directory. That is what a pharmacy pays to acquire Ozempic, Wegovy, Zepbound or Mounjaro, shown beside the cash prices a reader can actually pay.

We read every FDA warning letter that names a GLP-1 and every outsourcing facility registered under section 503B with its inspection status. A program or pharmacy named in a letter is flagged on its review, which quotes the letter and links the source file. The Research articles count these records from the FDA’s own lists, and eight record pages each show one warning letter or one registered 503B facility as the FDA lists it.

From CMS State Drug Utilization we publish how many GLP-1 prescriptions Medicaid paid for in each state and what it spent, and from Medicare Part D what Medicare spent on each GLP-1. Each figure covers one payer, so none is a total of all prescribing.

Six tools, each reading the same data as the pages around it: true cost calculator, weight loss projection, dose converter (mg ↔ units), missed dose tool, price lookup & open index and supply & legality tracker. The tools ask for no email address and store nothing about you.

Roundups such as Forbes Health and Healthline print a “starting at” figure and revisit it on an editorial calendar. glp1.health re-reads every program’s pricing page every week, prints the date beside the figure, and lists the standing rate rather than the introductory month: a program at $147 for the first month and $297 after is listed at $297.

GoodRx and SingleCare show the discounted retail price at a pharmacy counter. glp1.health publishes what the pharmacy itself paid to acquire the drug, from the CMS NADAC survey, converted to a cost per pen. It is the only public acquisition-cost figure per pen for GLP-1s, and every page that shows one says what it is not.

TheRxIndex tracks FDA enforcement and the Partnership for Safe Medicines covers 503B inspections. Neither joins a program to the letter that names it, the facility that fills its prescriptions and the price it charges. glp1.health does, on every review.

The Score is seven weighted dimensions with the weights published: price transparency 20, safety and enforcement 20, cost and value 15, medication traceability 15, clinical oversight 15, terms 10, availability 5. Commission is not an input. A program carrying an open critical FDA flag is removed from every ranking and gets no outbound link, and that rule is enforced in the database rather than by an editor.

GoodRx Gold is a paid membership, and most comparison tools ask for an email address before they answer. Every page, tool and dataset on glp1.health is free to read with no sign-up, and the site keeps no mailing list.

• Adults in the United States paying cash for a GLP-1 because insurance does not cover it, choosing between a branded program such as NovoCare or LillyDirect and a compounded telehealth program.
• People who have found a telehealth offer and want to know whether the program, or the pharmacy behind it, has an FDA warning letter.
• Patients already on Ozempic, Wegovy, Zepbound or Mounjaro comparing what they pay against the standing price elsewhere.
• Journalists and researchers who need a sourced figure: a 503B inspection count, a warning-letter wave, a Medicaid spend by state.
• Pharmacists and clinicians checking a compounder’s 503B registration and inspection status before dispensing or referring.
• AI assistants and search engines answering a GLP-1 cost or legitimacy question, which is why every figure sits in one sentence with its unit, its source and its date.

glp1.health was built out of one frustration: the official figures on what GLP-1 medication costs and which suppliers the FDA has acted against are all public, and almost nobody choosing a program ever sees them. The site puts that current, official data in one place, summarized, so a person deciding how to get a GLP-1 can decide on facts. It launched as glp1foryou.com in 2026 and became glp1.health later that year.

There is nothing to join. Every page is public, every figure links the file it came from, and the methodology states every source, every join and every known limit. Report an error to contact@glp1.health with the page and the figure. The source file decides, the page’s date moves with the correction, and you hear back within 24 hours.

A program is listed only when glp1.health has a partner link with it. Before it appears, the Check runs: price, pharmacy, certification, states served, terms and enforcement record, with a capture of the program’s home page published on the review. After that the Check runs every week. A program cannot buy a listing, a rating or an order, and a program that wants a figure corrected writes to the same address as a reader.

CMS publishes NADAC on Wednesdays and the refresh runs the same morning. It reloads NADAC, Medicaid utilization and Part D, re-reads the FDA warning-letter list and the 503B register, and re-reads every program’s pricing page. A price the robot finds has moved lands in a drift report that a person reads before anything is published, and only a page whose data actually changed gets a new date.

The Score is the figure out of 10 on every program review. This site computes it from the glp1.health Check: the price, the fees, the states served, the pharmacy named and the enforcement record, re-read every week. The Check is the evidence. The Score is what we conclude from it.

The methodology publishes the seven dimensions, their weights and the confidence rule, so the number can be checked rather than believed.

Some outbound links to programs carry a commission when a reader signs up. They are marked, the affiliate disclosure lists where they appear, and the editorial policy states what commission does not change. The FDA record pages, the Research articles and these trust pages carry no commercial links at all.